DarioHealth Corp DRIO.OQ DRIO.O is expected to show a rise in quarterly revenue when it reports results on November 7 for the period ending September 30 2024
The New York City-based company is expected to report a 110.3% increase in revenue to $7.397 million from $3.52 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for DarioHealth Corp is for a loss of 27 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for DarioHealth Corp is 3.50, above its last closing price of $0.89.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.55 | -0.55 | -0.08 | Beat | 85.6 |
Jan. 1 2024 | -0.48 | -0.40 | -0.20 | Beat | 50.6 |
Dec. 31 2023 | -0.54 | -0.55 | -0.50 | Beat | 9.6 |
Sep. 30 2023 | -0.48 | -0.46 | -0.49 | Missed | -6.5 |
Jan. 1 0001 | -0.57 | -0.52 | -0.58 | Missed | -11.1 |
Jan. 1 0001 | -0.49 | -0.50 | -0.45 | Beat | 9.6 |
Dec. 31 2022 | -0.56 | -0.65 | -0.51 | Beat | 21.8 |
Sep. 30 2022 | -0.71 | -0.76 | -0.64 | Beat | 16.1 |
This summary was machine generated November 6 at 14:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)